Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose, such as heroin, morphine, and oxycodone overdose. It works by blocking the effects of opioids on the central nervous system and reversing the life-threatening depression of the central nervous system and respiratory system that can occur. It has a fast onset and duration of action of 20 to 90 minutes.

The global U.S. Naloxone Market is estimated to be valued at US$ 1,390.7 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing opioid overdose cases due to rising opioid addiction in the United States is a major driver for the growth of the naloxone market. According to the Center for Disease Control and Prevention (CDC), every day over 130 people die due to an opioid overdose. There were over 70,000 drug overdose deaths in the U.S. in 2019, and around 47,500 were directly attributed to opioids. Increasing initiatives by naloxone manufacturers and public health organizations to promote take-home naloxone programs and usage of naloxone for emergency treatment are also fueling market growth. Moreover, growing awareness and acceptance of naloxone usage among first responders and laypersons for opioid crisis management is expected to create lucrative opportunities for the U.S. naloxone market over the forecast period.

Porter’s Analysis

Threat of new entrants: Low barrier to entry but established key players dominate the market. Regulations ensure patient safety which disadvantages new entrants.

Bargaining power of buyers: Individual consumers have low bargaining power but group purchasers like hospitals and government agencies have higher bargaining power to negotiate on price and delivery terms.

Bargaining power of suppliers: Few manufacturers for active ingredients restrict suppliers' bargaining power. Established relationships ensure steady supply.

Threat of new substitutes: No viable substitutes exists currently given that naloxone is highly effective for opioid overdose.

Competitive rivalry: Intense competition among dominant players to gain market share by expanding product range and distribution channels.

SWOT Analysis

Strengths: High demand due to opioid crisis. Support from government bodies to expand access. Growing awareness about overdose reversal.

Weaknesses: Limited manufacturing facilities and suppliers. High RD costs for new drug delivery methods.

Opportunities: Untapped rural markets. New formulations like nasal spray and auto-injectors. Scope for generics post patent expiry of branded products.

Threats: Stringent regulations. Reimbursement issues. Impact of preventive measures on opioid abuse.

Key Takeaways

The global U.S. Naloxone market is expected to witness high growth at a CAGR of 10% over the forecast period, due to increasing prevalence of opioid overdoses. The market size for 2023 is estimated to be US$ 1,390.7 Mn.

The Midwest region currently dominates the market due to higher opioid prescription rates. The Northeast region is expected to grow at fastest pace supported by policies enabling wider distribution of naloxone.

Key players operating in the U.S. Naloxone market are Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals.